Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation

Description

The study aims to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation

Conditions

Multiple Sclerosis

Talk to us

Study Overview

On this page

Study Details

Study overview

The study aims to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation

Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation (MS-PEKOS)

Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation

Condition
Multiple Sclerosis
Intervention / Treatment

-

Contacts and Locations

East Hanover

Novartis Investigative site, East Hanover, New Jersey, United States, 07936

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Ability to use a mobile device or computer with broadband internet access (or data streaming available)
  • 2. Ability to read, understand, and respond in English
  • 3. Adult aged 18 years of age or over at the time of the survey
  • 4. Self-confirmed diagnosis of MS
  • 5. Prescribed either OMB or OCR SC and will receive their first injection (Day 0) followed by completing the study survey between Day 1 and Day 7
  • 1. Participated in an OMB or OCR randomized clinical trial
  • 2. Previously treated with OMB or OCR SC
  • 3. Cognitive impairment that impacts the patient's ability to participate in a survey study

Ages Eligible for Study

18 Years to 99 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Novartis Pharmaceuticals,

Study Record Dates

2025-08-29